Skip to main content
Fig. 2 | Clinical Sarcoma Research

Fig. 2

From: IDH1 or -2 mutations do not predict outcome and do not cause loss of 5-hydroxymethylcytosine or altered histone modifications in central chondrosarcomas

Fig. 2

Genotyping of central cartilaginous tumours. a The mutational spectrum for IDH1 in the central chondrosarcomas from the TMA. In total 37 samples harbored an IDH1 mutation, of which the most prevalent mutation is the R132C. Eight samples harbored an IDH2 R172S mutation. b Disease specific survival of patients with IDH mutated (R132C, R132H, R132G, R132l, R132S, R172S) chondrosarcomas compared to patients with wild-type IDH chondrosarcomas revealed no statistical significant difference (p = 0.183)

Back to article page

Clinical Sarcoma Research

ISSN: 2045-3329